Pub Date : 2023-12-01eCollection Date: 2023-01-01DOI: 10.15420/aer.2023.15
Juan Carlos Diaz, Mauricio Duque, Julian Aristizabal, Jorge Marin, Cesar Niño, Oriana Bastidas, Luis Miguel Ruiz, Carlos D Matos, Carolina Hoyos, Daniela Hincapie, Alejandro Velasco, Jorge E Romero
Cardiac resynchronisation therapy (CRT) reduces the risk of heart failure-related hospitalisations and all-cause mortality, as well as improving quality of life and functional status in patients with persistent heart failure symptoms despite optimal medical treatment and left bundle branch block. CRT has traditionally been delivered by implanting a lead through the coronary sinus to capture the left ventricular epicardium; however, this approach is associated with significant drawbacks, including a high rate of procedural failure, phrenic nerve stimulation, high pacing thresholds and lead dislodgement. Moreover, a significant proportion of patients fail to derive any significant benefit. Left bundle branch area pacing (LBBAP) has recently emerged as a suitable alternative to traditional CRT. By stimulating the cardiac conduction system physiologically, LBBAP can result in a more homogeneous left ventricular contraction and relaxation, thus having the potential to improve outcomes compared with conventional CRT strategies. In this article, the evidence supporting the use of LBBAP in patients with heart failure is reviewed.
{"title":"The Emerging Role of Left Bundle Branch Area Pacing for Cardiac Resynchronisation Therapy.","authors":"Juan Carlos Diaz, Mauricio Duque, Julian Aristizabal, Jorge Marin, Cesar Niño, Oriana Bastidas, Luis Miguel Ruiz, Carlos D Matos, Carolina Hoyos, Daniela Hincapie, Alejandro Velasco, Jorge E Romero","doi":"10.15420/aer.2023.15","DOIUrl":"10.15420/aer.2023.15","url":null,"abstract":"<p><p>Cardiac resynchronisation therapy (CRT) reduces the risk of heart failure-related hospitalisations and all-cause mortality, as well as improving quality of life and functional status in patients with persistent heart failure symptoms despite optimal medical treatment and left bundle branch block. CRT has traditionally been delivered by implanting a lead through the coronary sinus to capture the left ventricular epicardium; however, this approach is associated with significant drawbacks, including a high rate of procedural failure, phrenic nerve stimulation, high pacing thresholds and lead dislodgement. Moreover, a significant proportion of patients fail to derive any significant benefit. Left bundle branch area pacing (LBBAP) has recently emerged as a suitable alternative to traditional CRT. By stimulating the cardiac conduction system physiologically, LBBAP can result in a more homogeneous left ventricular contraction and relaxation, thus having the potential to improve outcomes compared with conventional CRT strategies. In this article, the evidence supporting the use of LBBAP in patients with heart failure is reviewed.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e29"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10762674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139085685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01eCollection Date: 2023-01-01DOI: 10.15420/aer.2023.09
Rajdip Dulai, Fatima Bangash, Ajay Sharma, Alex Cambridge, Geoff Wong, Wei Lim, David Farwell, Jason Garcia, Neil T Srinivansan
Catheter ablation is the treatment of choice for patients with symptomatic accessory pathways (APs) causing recurrent atrioventricular reciprocating tachycardia or in situations where APs conduct rapidly, posing a risk of sudden cardiac death. Conventional AP mapping relies on point-by-point assessment of local electrograms looking closely for pathway electrograms or early atrial or ventricular electrograms, which may be challenging and time consuming. Recently, open window mapping (OWM) using 3D navigational systems has emerged as a novel technique to help localise and ablate APs. OWM has significant advantages over conventional point-by-point mapping techniques. The purpose of this review is to summarise the currently available literature on the OWM technique and to highlight the technical aspects and mapping considerations for OWM, including specific cases demonstrating its utility.
导管消融术是治疗有症状的附属通路(AP)导致复发性房室往复性心动过速患者的首选方法,也是AP快速传导导致心脏性猝死风险患者的首选方法。传统的 AP 图谱绘制依赖于逐点评估局部电图,仔细观察通路电图或早期心房或心室电图,这可能具有挑战性且耗费时间。最近,使用三维导航系统的开窗测图(OWM)已成为一种帮助定位和消融 AP 的新技术。与传统的逐点映射技术相比,开窗映射具有明显优势。本综述旨在总结目前有关 OWM 技术的文献,并重点介绍 OWM 的技术方面和绘图注意事项,包括证明其实用性的具体病例。
{"title":"Open Window Mapping of Accessory Pathways: A Literature Review and Practical Guide.","authors":"Rajdip Dulai, Fatima Bangash, Ajay Sharma, Alex Cambridge, Geoff Wong, Wei Lim, David Farwell, Jason Garcia, Neil T Srinivansan","doi":"10.15420/aer.2023.09","DOIUrl":"10.15420/aer.2023.09","url":null,"abstract":"<p><p>Catheter ablation is the treatment of choice for patients with symptomatic accessory pathways (APs) causing recurrent atrioventricular reciprocating tachycardia or in situations where APs conduct rapidly, posing a risk of sudden cardiac death. Conventional AP mapping relies on point-by-point assessment of local electrograms looking closely for pathway electrograms or early atrial or ventricular electrograms, which may be challenging and time consuming. Recently, open window mapping (OWM) using 3D navigational systems has emerged as a novel technique to help localise and ablate APs. OWM has significant advantages over conventional point-by-point mapping techniques. The purpose of this review is to summarise the currently available literature on the OWM technique and to highlight the technical aspects and mapping considerations for OWM, including specific cases demonstrating its utility.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e28"},"PeriodicalIF":3.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139429255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-23eCollection Date: 2023-01-01DOI: 10.15420/aer.2023.06
Gonca Suna, Greg J Mellor
Sudden cardiac arrest (SCA) is a common cause of death. The majority of SCA is caused by ventricular arrhythmia due to underlying CHD. Aborted SCA with no apparent diagnosis after initial assessment with ECG, echocardiography and coronary assessment is referred to as unexplained cardiac arrest (UCA). Systematic evaluation of such patients may reveal a specific diagnosis in up to half of patients before a diagnosis of idiopathic VF is assigned. Specific diagnoses include inherited cardiac conditions, such as latent cardiomyopathies or inherited primary electrical disease. Identifying the cause of UCA is therefore not only critical for appropriate management of the SCA survivors to prevent recurrence, but also for their family members who may be at risk of the same condition. This review provides a tiered, systematic approach for the investigation of UCA.
心脏骤停(SCA)是一种常见的死亡原因。大多数 SCA 是由潜在的心脏病导致的室性心律失常引起的。在使用心电图、超声心动图和冠状动脉评估进行初步评估后仍无明显诊断的中止型 SCA 被称为原因不明的心脏骤停(UCA)。对此类患者进行系统评估后,最多可发现半数患者有明确诊断,然后再做出特发性室颤的诊断。具体诊断包括遗传性心脏病,如潜伏性心肌病或遗传性原发性心电疾病。因此,确定 UCA 的病因不仅对适当管理 SCA 幸存者以防止复发至关重要,而且对可能面临同样病情风险的家庭成员也至关重要。本综述为 UCA 的调查提供了一种分层、系统的方法。
{"title":"Explaining the Unexplained: A Practical Approach to Investigating the Cardiac Arrest Survivor.","authors":"Gonca Suna, Greg J Mellor","doi":"10.15420/aer.2023.06","DOIUrl":"https://doi.org/10.15420/aer.2023.06","url":null,"abstract":"<p><p>Sudden cardiac arrest (SCA) is a common cause of death. The majority of SCA is caused by ventricular arrhythmia due to underlying CHD. Aborted SCA with no apparent diagnosis after initial assessment with ECG, echocardiography and coronary assessment is referred to as unexplained cardiac arrest (UCA). Systematic evaluation of such patients may reveal a specific diagnosis in up to half of patients before a diagnosis of idiopathic VF is assigned. Specific diagnoses include inherited cardiac conditions, such as latent cardiomyopathies or inherited primary electrical disease. Identifying the cause of UCA is therefore not only critical for appropriate management of the SCA survivors to prevent recurrence, but also for their family members who may be at risk of the same condition. This review provides a tiered, systematic approach for the investigation of UCA.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e27"},"PeriodicalIF":3.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138827912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-22eCollection Date: 2023-01-01DOI: 10.15420/aer.2023.07
Rohin K Reddy, James P Howard, Yousif Ahmad, Matthew J Shun-Shin, Florentina A Simader, Alejandra A Miyazawa, Keenan Saleh, Akriti Naraen, Jack W Samways, George Katritsis, Jagdeep S Mohal, Nandita Kaza, Bradley Porter, Daniel Keene, Nicholas Wf Linton, Darrel P Francis, Zachary I Whinnett, Vishal Luther, Prapa Kanagaratnam, Ahran D Arnold
Background: The prognostic impact of ventricular tachycardia (VT) catheter ablation is an important outstanding research question. We undertook a reconstructed individual patient data meta-analysis of randomised controlled trials comparing ablation to medical therapy in patients developing VT after MI.
Methods: We systematically identified all trials comparing catheter ablation to medical therapy in patients with VT and prior MI. The prespecified primary endpoint was reconstructed individual patient assessment of all-cause mortality. Prespecified secondary endpoints included trial-level assessment of all-cause mortality, VT recurrence or defibrillator shocks and all-cause hospitalisations. Prespecified subgroup analysis was performed for ablation approaches involving only substrate modification without VT activation mapping. Sensitivity analyses were performed depending on the proportion of patients with prior MI included.
Results: Eight trials, recruiting a total of 874 patients, were included. Of these 874 patients, 430 were randomised to catheter ablation and 444 were randomised to medical therapy. Catheter ablation reduced all-cause mortality compared with medical therapy when synthesising individual patient data (HR 0.63; 95% CI [0.41-0.96]; p=0.03), but not in trial-level analysis (RR 0.91; 95% CI [0.67-1.23]; p=0.53; I2=0%). Catheter ablation significantly reduced VT recurrence, defibrillator shocks and hospitalisations compared with medical therapy. Sensitivity analyses were consistent with the primary analyses.
Conclusion: In patients with postinfarct VT, catheter ablation reduces mortality.
背景:室性心动过速(VT)导管消融对预后的影响是一个尚未解决的重要研究问题。我们对心肌梗死后发生室速的患者进行了随机对照试验,比较了消融与药物治疗,并对这些试验的单个患者数据进行了重建荟萃分析:我们系统地确定了所有对既往有心肌梗死的 VT 患者进行导管消融与药物治疗比较的试验。预设的主要终点是患者个人对全因死亡率的重建评估。预设的次要终点包括全因死亡率、VT 复发或除颤器电击以及全因住院的试验水平评估。对于只涉及基质改变而不涉及 VT 激活图谱的消融方法,进行了预先指定的亚组分析。根据纳入的既往有心肌梗死的患者比例进行了敏感性分析:结果:共纳入了八项试验,招募了 874 名患者。在这874名患者中,430人被随机分配接受导管消融治疗,444人被随机分配接受药物治疗。与药物治疗相比,导管消融术降低了全因死亡率(HR 0.63;95% CI [0.41-0.96];P=0.03),但在试验层面的分析中却没有降低(RR 0.91;95% CI [0.67-1.23];P=0.53;I2=0%)。与药物治疗相比,导管消融大大降低了VT复发率、除颤器电击率和住院率。敏感性分析结果与主要分析结果一致:导管消融术可降低梗死后 VT 患者的死亡率。
{"title":"Catheter Ablation for Ventricular Tachycardia After MI: A Reconstructed Individual Patient Data Meta-analysis of Randomised Controlled Trials.","authors":"Rohin K Reddy, James P Howard, Yousif Ahmad, Matthew J Shun-Shin, Florentina A Simader, Alejandra A Miyazawa, Keenan Saleh, Akriti Naraen, Jack W Samways, George Katritsis, Jagdeep S Mohal, Nandita Kaza, Bradley Porter, Daniel Keene, Nicholas Wf Linton, Darrel P Francis, Zachary I Whinnett, Vishal Luther, Prapa Kanagaratnam, Ahran D Arnold","doi":"10.15420/aer.2023.07","DOIUrl":"10.15420/aer.2023.07","url":null,"abstract":"<p><strong>Background: </strong>The prognostic impact of ventricular tachycardia (VT) catheter ablation is an important outstanding research question. We undertook a reconstructed individual patient data meta-analysis of randomised controlled trials comparing ablation to medical therapy in patients developing VT after MI.</p><p><strong>Methods: </strong>We systematically identified all trials comparing catheter ablation to medical therapy in patients with VT and prior MI. The prespecified primary endpoint was reconstructed individual patient assessment of all-cause mortality. Prespecified secondary endpoints included trial-level assessment of all-cause mortality, VT recurrence or defibrillator shocks and all-cause hospitalisations. Prespecified subgroup analysis was performed for ablation approaches involving only substrate modification without VT activation mapping. Sensitivity analyses were performed depending on the proportion of patients with prior MI included.</p><p><strong>Results: </strong>Eight trials, recruiting a total of 874 patients, were included. Of these 874 patients, 430 were randomised to catheter ablation and 444 were randomised to medical therapy. Catheter ablation reduced all-cause mortality compared with medical therapy when synthesising individual patient data (HR 0.63; 95% CI [0.41-0.96]; p=0.03), but not in trial-level analysis (RR 0.91; 95% CI [0.67-1.23]; p=0.53; I<sup>2</sup>=0%). Catheter ablation significantly reduced VT recurrence, defibrillator shocks and hospitalisations compared with medical therapy. Sensitivity analyses were consistent with the primary analyses.</p><p><strong>Conclusion: </strong>In patients with postinfarct VT, catheter ablation reduces mortality.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e26"},"PeriodicalIF":2.6,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138827911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-26eCollection Date: 2023-01-01DOI: 10.15420/aer.2023.14
Demosthenes G Katritsis, Hugh Calkins
{"title":"Septal and Conduction System Pacing.","authors":"Demosthenes G Katritsis, Hugh Calkins","doi":"10.15420/aer.2023.14","DOIUrl":"10.15420/aer.2023.14","url":null,"abstract":"","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e25"},"PeriodicalIF":2.6,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/17/aer-12-e25.PMC10583155.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49673778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30eCollection Date: 2023-01-01DOI: 10.15420/aer.2022.35
Akriti Naraen, Dileep Duvva, Archana Rao
Guidelines help clinicians to deliver high-quality care with therapies based on up-to-date evidence. There has been significant progress in the management of heart failure with regards to both medication and cardiac device therapy. These advances have been incorporated into national and international guidelines with varying degrees of success. This article reviews current guidance from the National Institute of Health and Care Excellence in the UK and compares this with European Society of Cardiology guidelines, and evaluates how differences between them may impact on clinical practice.
指南有助于临床医生根据最新证据提供高质量的治疗。在药物和心脏设备治疗方面,心力衰竭的管理取得了重大进展。这些进展已被纳入国家和国际指南,并取得了不同程度的成功。本文回顾了英国国家健康与护理卓越研究所(National Institute of Health and Care Excellence)的现行指南,并将其与欧洲心脏病学会(European Society of Cardiology)的指南进行了比较,评估了两者之间的差异可能对临床实践产生的影响。
{"title":"Heart Failure and Cardiac Device Therapy: A Review of Current National Institute of Health and Care Excellence and European Society of Cardiology Guidelines.","authors":"Akriti Naraen, Dileep Duvva, Archana Rao","doi":"10.15420/aer.2022.35","DOIUrl":"10.15420/aer.2022.35","url":null,"abstract":"<p><p>Guidelines help clinicians to deliver high-quality care with therapies based on up-to-date evidence. There has been significant progress in the management of heart failure with regards to both medication and cardiac device therapy. These advances have been incorporated into national and international guidelines with varying degrees of success. This article reviews current guidance from the National Institute of Health and Care Excellence in the UK and compares this with European Society of Cardiology guidelines, and evaluates how differences between them may impact on clinical practice.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e21"},"PeriodicalIF":2.6,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/d0/aer-12-e21.PMC10345955.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-24eCollection Date: 2023-01-01DOI: 10.15420/aer.2022.13
Joanne K Taylor, Fozia Zahir Ahmed
Research examining the utility of cardiac device data to manage patients with heart failure (HF) is rapidly evolving. COVID-19 has reignited interest in remote monitoring, with manufacturers each developing and testing new ways to detect acute HF episodes, risk stratify patients and support self-care. As standalone diagnostic tools, individual physiological metrics and algorithm-based systems have demonstrated utility in predicting future events, but the integration of remote monitoring data with existing clinical care pathways for device HF patients is not well described. This narrative review provides an overview of device-based HF diagnostics available to care providers in the UK, and describes the current state of play with regard to how these systems fit in with current HF management.
{"title":"Clinical Pathways Guided by Remotely Monitoring Cardiac Device Data: The Future of Device Heart Failure Management?","authors":"Joanne K Taylor, Fozia Zahir Ahmed","doi":"10.15420/aer.2022.13","DOIUrl":"10.15420/aer.2022.13","url":null,"abstract":"<p><p>Research examining the utility of cardiac device data to manage patients with heart failure (HF) is rapidly evolving. COVID-19 has reignited interest in remote monitoring, with manufacturers each developing and testing new ways to detect acute HF episodes, risk stratify patients and support self-care. As standalone diagnostic tools, individual physiological metrics and algorithm-based systems have demonstrated utility in predicting future events, but the integration of remote monitoring data with existing clinical care pathways for device HF patients is not well described. This narrative review provides an overview of device-based HF diagnostics available to care providers in the UK, and describes the current state of play with regard to how these systems fit in with current HF management.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e15"},"PeriodicalIF":3.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/88/aer-12-e15.PMC10326671.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9812528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-13eCollection Date: 2023-01-01DOI: 10.15420/aer.2022.41
Nadeev Wijesuriya, Felicity De Vere, Vishal Mehta, Steven Niederer, Christopher A Rinaldi, Jonathan M Behar
Leadless pacing is a rapidly growing field. Initially designed to provide right ventricular pacing for those who were contraindicated for conventional devices, the technology is growing to explore the potential benefit of avoiding long-term transvenous leads in any patient who requires pacing. In this review, we first examine the safety and performance of leadless pacing devices. We then review the evidence for their use in special populations, such as patients with high risk of device infection, patients on haemodialysis, and patients with vasovagal syncope who represent a younger population who may wish to avoid transvenous pacing. We also summarise the evidence for leadless cardiac resynchronisation therapy and conduction system pacing and discuss the challenges of managing issues, such as system revisions, end of battery life and extractions. Finally, we discuss future directions in the field, such as completely leadless cardiac resynchronisation therapy-defibrillator devices and whether leadless pacing has the potential to become a first-line therapy in the near future.
{"title":"Leadless Pacing: Therapy, Challenges and Novelties.","authors":"Nadeev Wijesuriya, Felicity De Vere, Vishal Mehta, Steven Niederer, Christopher A Rinaldi, Jonathan M Behar","doi":"10.15420/aer.2022.41","DOIUrl":"10.15420/aer.2022.41","url":null,"abstract":"<p><p>Leadless pacing is a rapidly growing field. Initially designed to provide right ventricular pacing for those who were contraindicated for conventional devices, the technology is growing to explore the potential benefit of avoiding long-term transvenous leads in any patient who requires pacing. In this review, we first examine the safety and performance of leadless pacing devices. We then review the evidence for their use in special populations, such as patients with high risk of device infection, patients on haemodialysis, and patients with vasovagal syncope who represent a younger population who may wish to avoid transvenous pacing. We also summarise the evidence for leadless cardiac resynchronisation therapy and conduction system pacing and discuss the challenges of managing issues, such as system revisions, end of battery life and extractions. Finally, we discuss future directions in the field, such as completely leadless cardiac resynchronisation therapy-defibrillator devices and whether leadless pacing has the potential to become a first-line therapy in the near future.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e09"},"PeriodicalIF":2.6,"publicationDate":"2023-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/44/aer-12-e09.PMC10326662.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-12eCollection Date: 2023-01-01DOI: 10.15420/aer.2022.34
Yaacoub Chahine, Matthew J Magoon, Bahetihazi Maidu, Juan C Del Álamo, Patrick M Boyle, Nazem Akoum
Stroke is a leading cause of death worldwide. With escalating healthcare costs, early non-invasive stroke risk stratification is vital. The current paradigm of stroke risk assessment and mitigation is focused on clinical risk factors and comorbidities. Standard algorithms predict risk using regression-based statistical associations, which, while useful and easy to use, have moderate predictive accuracy. This review summarises recent efforts to deploy machine learning (ML) to predict stroke risk and enrich the understanding of the mechanisms underlying stroke. The surveyed body of literature includes studies comparing ML algorithms with conventional statistical models for predicting cardiovascular disease and, in particular, different stroke subtypes. Another avenue of research explored is ML as a means of enriching multiscale computational modelling, which holds great promise for revealing thrombogenesis mechanisms. Overall, ML offers a new approach to stroke risk stratification that accounts for subtle physiologic variants between patients, potentially leading to more reliable and personalised predictions than standard regression-based statistical associations.
{"title":"Machine Learning and the Conundrum of Stroke Risk Prediction.","authors":"Yaacoub Chahine, Matthew J Magoon, Bahetihazi Maidu, Juan C Del Álamo, Patrick M Boyle, Nazem Akoum","doi":"10.15420/aer.2022.34","DOIUrl":"10.15420/aer.2022.34","url":null,"abstract":"<p><p>Stroke is a leading cause of death worldwide. With escalating healthcare costs, early non-invasive stroke risk stratification is vital. The current paradigm of stroke risk assessment and mitigation is focused on clinical risk factors and comorbidities. Standard algorithms predict risk using regression-based statistical associations, which, while useful and easy to use, have moderate predictive accuracy. This review summarises recent efforts to deploy machine learning (ML) to predict stroke risk and enrich the understanding of the mechanisms underlying stroke. The surveyed body of literature includes studies comparing ML algorithms with conventional statistical models for predicting cardiovascular disease and, in particular, different stroke subtypes. Another avenue of research explored is ML as a means of enriching multiscale computational modelling, which holds great promise for revealing thrombogenesis mechanisms. Overall, ML offers a new approach to stroke risk stratification that accounts for subtle physiologic variants between patients, potentially leading to more reliable and personalised predictions than standard regression-based statistical associations.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e07"},"PeriodicalIF":2.6,"publicationDate":"2023-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/9f/aer-12-e07.PMC10326666.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Radiation-associated cardiovascular disease, an increasingly recognised disease process, is a significant adverse effect of radiation therapy for common malignancies that involve the chest, and include lymphomas, lung, mediastinal and breast cancers. Two factors contribute to the increasing incidence of radiation-associated cardiovascular disease: advances in malignancy detection and the improved survival of cancer patients, by which many symptoms of radiation-associated cardiovascular disease, specifically radiation-associated arrhythmias, present years and/or decades following initial radiotherapy. We present a focused overview of the currently understood pathophysiology, prevalence and management strategies of radiation-associated arrhythmias, which include bradyarrhythmias, tachyarrhythmias and autonomic dysfunction.
{"title":"Radiation-associated Arrhythmias: Putative Pathophysiological Mechanisms, Prevalence, Screening and Management Strategies.","authors":"Rohil Bedi, Ali Ahmad, Piotr Horbal, Philip L Mar","doi":"10.15420/aer.2022.44","DOIUrl":"https://doi.org/10.15420/aer.2022.44","url":null,"abstract":"<p><p>Radiation-associated cardiovascular disease, an increasingly recognised disease process, is a significant adverse effect of radiation therapy for common malignancies that involve the chest, and include lymphomas, lung, mediastinal and breast cancers. Two factors contribute to the increasing incidence of radiation-associated cardiovascular disease: advances in malignancy detection and the improved survival of cancer patients, by which many symptoms of radiation-associated cardiovascular disease, specifically radiation-associated arrhythmias, present years and/or decades following initial radiotherapy. We present a focused overview of the currently understood pathophysiology, prevalence and management strategies of radiation-associated arrhythmias, which include bradyarrhythmias, tachyarrhythmias and autonomic dysfunction.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e24"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/48/aer-12-e24.PMC10481379.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}